News Information
Focusing on cutting-edge technology and conveying industry voices
In the height of summer, when scientific research is at its peak, are you held back by the challenges of membrane protein expression and the high costs of trial-and-error experimentation? Suzhou Perotin Bio’s Summer Research Support Program is now officially launched! Leveraging our proprietary cell-free expression technology, we’ll help you assess the feasibility of expressing your target membrane protein—at zero cost—efficiently addressing the common experimental hurdles of difficult expression and low yields, and accelerating your research progress!
2026/06/29
July 24–26, 2026 (full-day registration on the 24th) Nanjing City, Jiangsu Province (Guangyuan Holiday Hotel ★★★★★), Intersection of Binhu West Road and Innovation Middle Road, Jiangning District, Nanjing
2026/06/17
Highlights | When AI Meets Cell-Free Protein Expression, New Drug Development Ushers in a New Era
On June 4–5, the 2026 Pharma Future Summit was held as scheduled at the Kempinski Hotel Suzhou Jinji Lake. At the AI session, Gan Mingzhe, Deputy General Manager of Suzhou Perotin Biotechnology Co., Ltd., delivered a keynote presentation, detailing the integration of cell-free protein expression with artificial intelligence and offering fresh insights to address the industry’s key challenges in AI-driven drug development.
2026/06/10
In protein engineering and antibody–drug conjugate (ADC) research, achieving “precise site-specific modification” of proteins has long been a critical scientific challenge. Traditional protein‑modification strategies typically rely on random reactions with the side chains of natural amino acids, leading to inherent uncertainties in modification sites, modification ratios, and product heterogeneity—factors that significantly impact both functional studies and drug development. In recent years, a biological strategy based on Genetic Code Expansion (GCE) has gained increasing attention. By reprogramming the protein translation machinery, this approach incorporates non‑natural amino acids at predefined codon positions during protein synthesis, enabling precise structural design of proteins at the expression stage. Unlike conventional methods that depend on post‑translational modifications, GCE shifts the control point upstream to the protein biosynthesis process itself, transforming protein modification from a stochastic event into a programmable, translational‑level process. This dramatically enhances the specificity and consistency of site‑directed modifications. This strategy offers a more precise and controllable biological platform for applications such as antibody–drug conjugation, protein labeling, and the design of functional proteins. In this live session, we will explore the principles and applications of site‑specific incorporation of non‑natural amino acids, highlighting their significance in ADC development and protein engineering.
2026/06/10
On June 4–5, the 2026 Pharma Future Summit will grandly open at the Kempinski Hotel Suzhou Jinji Lake. This year’s summit adopts a holistic, full‑industry‑chain perspective, bringing together top decision‑makers to build a closed-loop, collaborative ecosystem. It focuses on breaking through barriers in the industrialization of cutting-edge technologies and on global strategic planning, reshaping the paradigm of pharmaceutical innovation and collaboration. Sub‑Venue 7: AI Session Keynote Topic 1: “The Revolution of AI in Drug Discovery” Cui Jinhui, CEO of Suzhou Perotin Bio: “Generative AI Coupled with Cell-Free Protein Expression: Empowering Innovation at the Source of Drug Development” 📍June 4–5, Kempinski Hotel Suzhou Jinji Lake
2026/05/28
To establish a platform for research collaboration between universities and enterprises, disseminate cutting-edge biotechnological innovations, and support the advancement of research and education in synthetic biology and biopharmaceuticals, on May 25, Perotin Bio, in partnership with the Kasma Platform, visited the Southern University of Science and Technology to jointly foster campus‑based scientific innovation.
2026/05/26
How many “stumbling blocks” have you encountered on the path of research and development? In the discovery of innovative drug targets and cutting-edge basic research, there are always certain proteins that leave conventional cell expression systems—such as E. coli or mammalian cells—completely stumped: Membrane proteins that precipitate as soon as they’re expressed? Toxic proteins that cause host cells to die upon expression? Or highly unstable proteins with extremely complex structures that degrade easily?…
2026/05/21
免费试用 | 从靶点到药物：珀罗汀全长4次跨膜Claudin-6蛋白，成实体瘤靶向研发“关键利器”
Claudin‑6 is a member of the tight junction protein family, containing four transmembrane domains. It plays an important role during embryonic development and is expressed in fetal tissues such as the stomach, pancreas, lung, and kidney. It is one of the earliest epithelial fate‑determining proteins to be expressed in embryonic stem (ES) cells and serves as a cell‑surface–specific marker for human pluripotent stem cells (HPSCs).
2025/12/24
Contact Information
Service Hotline: +86-512-67900128
Customer Service: order@sz-pld.tech
Business Cooperation: bd@sz-pld.tech
Address: Room 302, Building 1, Weili Medical Science and Technology Park, No. 69 Jiepu Road, Suzhou Industrial Park
